<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">MORICIZINE</span><br/>(mor-i'ci-zeen)<br/><span class="topboxtradename">Ethmozine<br/></span><b>Classifications:</b> <span class="classification">cardiovascular agent</span>; <span class="classification">antiarrhythmic agent, class ic</span><br/><b>Prototype: </b>Flecainide<br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>200 mg, 250 mg, 300 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Class IC antiarrhythmic agent with potent local anesthetic effect and myocardial membrane stabilizing effects. Shortens phase
         II and phase III repolarization, resulting in a decreased action potential duration and effective refractory period of the
         cardiac muscle. Decrease in the maximum rate of phase 0 depolarization (V<sub>max</sub>) occurs. Sinus node and atrial tissue are not affected.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Prolongs atrioventricular conduction in patients with ventricular tachycardia. In patients with impaired left ventricular
         functioning, has minimal effects on cardiac index, pulmonary wedge pressure, and ejection fraction, either at rest or during
         exercise.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of ventricular tachycardia and ventricular premature depolarizations.</p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Supraventricular arrhythmias.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Preexisting second- and third-degree AV block, right bundle branch block unless a pacemaker is used; cardiogenic shock; hypersensitivity
         to moricizine; lactation.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Non-life-threatening arrhythmia; hypokalemia, hyperkalemia, hypomagnesia; sick sinus syndrome; hepatic impairment, renal impairment;
         pregnancy (category B). Safety and efficacy in children 
      </p><h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Ventricular and Supraventricular Arrhythmias</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 200300 mg q8h<br/><br/><span class="impairmenttitle">Renal Hepatic or Impairment</span><br/>Start with 600 mg/d or less<br/><br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Withdraw previous drug for 12 half-lives before transferring to moricizine.</li>
<li>Dose increments are usually limited to 150 mg/d at 3-d intervals.</li>
<li>Store at 15°30° C (59°86° F) unless otherwise directed by manufacturer.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CV:</span>
<span class="speceff-life">Arrhythmias, including PVCs and ventricular tachycardia</span>. <span class="typehead">CNS:</span>
<span class="speceff-common">Dizziness, light-headedness, anxiety, headache, euphoria, perioral numbness.</span>
<span class="typehead">GI:</span> Nausea, diarrhea, dry mouth, abdominal discomfort. <span class="typehead">Body as a Whole:</span> Hyperthermia (rare). 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> May decrease <b>theophylline</b> concentrations. May increase the hypoprothrombinemic effects of <b>warfarin.</b>
<h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from GI tract. 3040% reaches systemic circulation due to extensive first-pass metabolism. <span class="typehead">Onset:</span> 2 h. <span class="typehead">Peak:</span> 1014 h. <span class="typehead">Duration:</span> 10 h. <span class="typehead">Distribution:</span> 9295% bound to plasma proteins. Distributed into breast milk. <span class="typehead">Metabolism:</span> Extensively metabolized in the liver. <span class="typehead">Elimination:</span> 39% excreted in urine over 2 d, 56% excreted in feces over 45 d. <span class="typehead">Half-Life:</span> elimination 10 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Baseline serum electrolytes, liver and kidney function tests.</li>
<li>Correct electrolyte imbalances, especially hypo/hyperkalemia and hypomagnesemia prior to beginning drug.</li>
<li>Monitor cardiac status at beginning and throughout therapy closely because drug may cause serious new arrhythmias or worsening
            of preexisting arrhythmias.
         </li>
<li>Monitor patients with liver or kidney dysfunction closely for adverse effects.</li>
<li>Monitor patients with sick sinus syndrome or conduction abnormalities carefully. Drug may interfere with sinus activity or
            cause AV block, both of which may necessitate prompt withdrawal of drug.
         </li>
<li>Use precautions for dizziness; it occurs <img src="../images/special/greaterorequal.gif"/>15% of those taking drug.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Understand seriousness of taking moricizine exactly as prescribed.</li>
<li>Take drug consistently with respect to meals.</li>
<li>Keep regular follow-up appointments while taking this drug.</li>
<li>Report immediately palpitations, irregular heartbeat, chest pains, or fever to physician.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>